Search Results
Oct 30, 2025, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
completed its rolling NDA submission for zidesamtinib in tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). Data supporting the NDA submission were
More news about: Nuvalent, Inc.
Oct 29, 2025, 16:05 ET TransMedics Reports Third Quarter 2025 Financial Results
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025.
More news about: TransMedics Group, Inc.
Oct 29, 2025, 10:30 ET Medical Milestone: Children's Hospital of Philadelphia Performs Its First Artificial Heart Surgery on Infant with Complex Congenital Heart Disease
PhD, Director of Mechanical Circulatory Support and ECMO, the Surgical Director of Cardiac Lymphatics, and the Surgical Director of the Heart and Lung Transplant Programs at CHOP. "As a team, we were faced with the daunting task of stabilizing him without conventional surgical options. We recognized
More news about: Children's Hospital of Philadelphia
Oct 29, 2025, 08:31 ET Redefining the future of transplant medicine at VCU Health
new lung transplant program—one of only three in Virginia—is already changing lives for patients with end-stage lung disease. A National Model
More news about: VCU Health
Oct 29, 2025, 08:30 ET Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response
leveraged Caris Life Sciences' extensive clinico-genomic database, analyzing outcomes in a real-world cohort of nearly 36,000 patients with non-small cell lung cancer (NSCLC) and over 25,000 colorectal (CRC) cancer patients. This dual approach provided insight and large-scale evidence supporting TET2-CH as
More news about: Caris Life Sciences
Oct 29, 2025, 08:11 ET AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in
More news about: AbbVie
Oct 29, 2025, 07:00 ET Gundry MD Announces the Launch of Longevitine Plus: A Revolutionary Longevity Support Formula
Gundry MD, Dr. Steven Gundry was one of the world's top cardiothoracic surgeons Currently, he's the medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Santa Barbara, California where he's spent the past 25 years helping people restore
More news about: Gundry MD
Oct 29, 2025, 06:23 ET Louisianans Can Get a Free Lung Cancer Screening Test During Lung Cancer Awareness Month
Under Louisiana Lung Cancer Screening Initiative, which runs through November 30, individuals can call a Lung Health Navigator at 844-ALA-LUNG (844-252-5864) to find out if they are eligible for a lung cancer screening. Lung Health Navigators can support callers by identifying nearby lung cancer screening
More news about: American Lung Association
Oct 29, 2025, 05:04 ET Lung Association Steps Up with $22 Million in Research Funding as Federal Support for Science Wavers
About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Oct 28, 2025, 12:00 ET New Report: Outdated Trains Are a Major Threat to Health; Cleaner Technologies Can Protect Workers and Communities
About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Oct 28, 2025, 11:19 ET Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program
More news about: Genprex, Inc.
Oct 28, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
in a Phase 3 IMPALA-2 pivotal clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis ("aPAP"), a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Savara has consistently represented that, based on investments
More news about: Pomerantz LLP
Oct 28, 2025, 09:31 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Oct 28, 2025, 08:36 ET Widow Honors Late Author Keith Scheid With Dragon Car Road Trip
https://keithscheid.com) did not survive his fierce battle with complications from his double-lung transplant in late 2023, but his legacy and adventurous spirit live on here. "To boost Keith's legacy and help new readers discover
More news about: Loretta Richardson-Scheid
Oct 28, 2025, 08:11 ET Fosun Pharma Announces 2025Q3 Financial Results
October, the U.S. bridging study of serplulimab injection in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) has completed enrollment of all 200 patients, laying a solid foundation for the subsequent submission of a Biologics License Application
More news about: Fosun Pharma
Oct 28, 2025, 08:03 ET Mercy BioAnalytics Publishes Validation Study in Gynecologic Oncology Demonstrating Unprecedented Performance of Blood Test for Early Detection of Ovarian Cancer
patients and their families. Mercy's initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number one cancer killer, takes more lives than breast and prostate cancers
More news about: Mercy BioAnalytics
Oct 28, 2025, 07:00 ET Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Combining REQORSA with Alectinib Further Increased Apoptosis
More news about: Genprex, Inc.
Oct 28, 2025, 07:00 ET In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
exchange from the lungs and reducing mechanical ventilation-induced lung injury - allowing the lungs to rest. However, ECMO alone does not remove the inflammatory cytokines and toxins that cause capillary leak and drive ongoing lung damage – the central problem in severe ARDS. But CytoSorb does."
More news about: Cytosorbents Corp
Oct 28, 2025, 03:45 ET Kanazawa University Research: Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells
thousands of times without causing severe damage, allowing nanoscale mapping of nuclear elasticity. The researchers found that human lung cancer cells (PC9) showed significantly increased nuclear elasticity under serum-free conditions. This stiffening correlated with increased trimethylation
More news about: Kanazawa University
Oct 28, 2025, 02:16 ET SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,
More news about: THE ROSEN LAW FIRM, P. A.
Oct 27, 2025, 14:00 ET Cizzle Bio CEO Bill Behnke Moderates High-Profile Panel on Value-Based Cancer Diagnostics at 2025 AVBCC Summit
Oct. 22 discussion underscored Cizzle Bio's commitment to redefining early detection through advancing blood-based, biomarker-driven diagnostics for lung and gastric cancers that integrate clinical, economic and patient-centered value. Panelists examined the full lifecycle of diagnostic innovation—from
More news about: Cizzle Bio
Oct 27, 2025, 11:09 ET 「2025香港原創潮玩展@吉隆坡」香港原創設計力量開拓東盟市場
「2025香港原創潮玩展@吉隆坡」五大展區將呈獻超過四百五十件香港原創潮玩，並設有珍貴資料圖片、錄像、AR互動拍攝專區，帶領觀眾穿越香港潮玩的創意時光。 五大展區焦點搶先看 —「巨匠潮玩」展區 — 展區由六位香港殿堂級原創潮玩設計師的作品坐鎮，包括（排名不分先後）Bee Wong、B.wing、Foon Wong、Kenny Wong、Lung Kasing及 Winson Ma將會展出他們最具代表性的作品，建構獨一無二的陳列空間。觀眾可以在此了解香港頂尖潮玩品牌的創作風格、理念和最新動向，一窺大師級的匠心獨運。 —「飛躍潮玩」展區 — 六位創意出衆的香港設計師，包括（排名不分先後）Felix
More news about: 創意創業會
Oct 27, 2025, 09:00 ET Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
i "Learn about Pulmonary Embolism," American Lung Association. Accessed on Oct. 7, 2025.
More news about: Penumbra, Inc.
Oct 27, 2025, 08:30 ET BioDlink Completes First International Shipment of Bevacizumab to Colombia
Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia [1] .
More news about: BioDlink Biopharm Co., Ltd.
Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
confusion, and vision problems. Lung Inflammation Cases of lung inflammation have happened in some people who receive STELARA® and may be serious. These lung problems may need to be treated in a hospital. Tell your healthcare provider
More news about: Johnson & Johnson